Business
Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025
CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025 Income StatementCosmos Health continued its positive trajectory in Q2 2025, delivering double-digit revenue growth of 11.66% and a 51.60% increase in gross profit. The Company remains on track to meet its profitability targets, driven by strong performance across multiple business units. For the first half of 2025, gross profit rose 53.00% to $3.21 million, with gross margin expanding by 374 basis points. Adjusted profitability also improved, with net loss narrowing, supported by higher-margin revenue growth and reduced cash operating expenses. Revenue for Q2 2025 was $14.75 million, an increase of 11.66% from $13.21 million in Q2 2024, and for the first half of 2025 revenue was $28.46 million, up 2.4% from $27.79 million in the prior-year period.Gross profit rose 51.60% year-over-year in Q2 2025 to $1.16 million, up from $0.77 million in the prior-year period, and for the first half of 2025 gross profit increased 53.0% to $3.21 million, compared to $2.10 million in the prior-year period.Gross margin expanded by 208 basis points to 7.89% in Q2 2025, compared to 5.81% in Q2 2024, and for the first half of 2025 gross margin expanded by 374 basis points to 11.30%, compared to 7.56% in the prior-year period.Total operating expenses were $3.81 million in Q2 2025, an increase from $3.27 million in Q2 2024, and for the first half of 2025 total operating expenses were $6.69 million, compared to $6.44 million in the prior-year period. Adjusted for non-cash items, cash operating expenses declined in the first half of 2025. EBITDA remained stable at ($2.19 million) in Q2 2025, compared to ($2.04 million) in Q2 2024, and for the first half of 2025 EBITDA improved to ($2.59 million), compared to ($3.52 million) in the prior-year period.Adjusted EBITDA was essentially unchanged at ($1.31 million) in Q2 2025, compared to ($1.32 million) in Q2 2024, and for the first half of 2025 adjusted EBITDA improved to ($1.14 million), compared to ($1.96 million) in the prior-year period.Adjusted net income (loss...